Difficulty: Medium
Average Score: 94%
Practice
You are evaluating a 6-year-old child with ALL on interim maintenance phase who has frequent mucositis and myelosuppression that needs frequent discontinuation of his treatment. Of the following, the MOST valuable test for this child is
Correct answer
B
Rationale
The most valuable test for the 6-year-old child with Acute Lymphoblastic Leukemia (ALL) experiencing frequent mucositis and myelosuppression, necessitating frequent treatment discontinuation, is pharmacogenetic testing of the thiopurine S-methyltransferase (TPMT) gene (Option B).
Pharmacogenetic testing of TPMT gene is crucial in this scenario because thiopurine drugs like mercaptopurine are commonly used in ALL treatment. TPMT enzyme activity affects how the body processes these drugs; individuals with low TPMT activity are at higher risk of severe myelosuppression. By identifying TPMT gene variations, clinicians can personalize drug dosages to minimize adverse effects and optimize treatment efficacy.
The other options are less relevant in this context:
A) Complete blood count (CBC) is a standard test but may not provide specific information on drug metabolism or toxicity related to thiopurine drugs.
C) Renal function test is important for monitoring kidney function but is not directly related to optimizing thiopurine drug therapy.
D) Bone marrow study is invasive and not indicated solely for assessing drug metabolism issues.
Educationally, understanding the role of pharmacogenetics in pediatric oncology highlights the importance of personalized medicine in improving treatment outcomes and reducing adverse effects in children with cancer. By incorporating genetic testing into clinical practice, healthcare providers can tailor treatments to individual genetic profiles, leading to more effective and safer therapies for pediatric patients.
Pharmacogenetic testing of TPMT gene is crucial in this scenario because thiopurine drugs like mercaptopurine are commonly used in ALL treatment. TPMT enzyme activity affects how the body processes these drugs; individuals with low TPMT activity are at higher risk of severe myelosuppression. By identifying TPMT gene variations, clinicians can personalize drug dosages to minimize adverse effects and optimize treatment efficacy.
The other options are less relevant in this context:
A) Complete blood count (CBC) is a standard test but may not provide specific information on drug metabolism or toxicity related to thiopurine drugs.
C) Renal function test is important for monitoring kidney function but is not directly related to optimizing thiopurine drug therapy.
D) Bone marrow study is invasive and not indicated solely for assessing drug metabolism issues.
Educationally, understanding the role of pharmacogenetics in pediatric oncology highlights the importance of personalized medicine in improving treatment outcomes and reducing adverse effects in children with cancer. By incorporating genetic testing into clinical practice, healthcare providers can tailor treatments to individual genetic profiles, leading to more effective and safer therapies for pediatric patients.